Drug intelligence / Profile preview

BCI-1038

Development stage: Unknown
Lead developer: BrainCells
Modality: Small Molecules
Administration: Oral

Overview

BCI-1038 is a pro-drug candidate developed by BrainCells Inc. It is currently undergoing evaluation in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetic profile in healthy male subjects. Administered as a single oral dose, BCI-1038 is one of several new pro-drugs being investigated, and it is being compared to BCI-838 and its active metabolite BCI-632. This suggests that BCI-1038 is designed to deliver BCI-632 as its active therapeutic agent.

Other names: BCI-632BCI632BCI 632MGS0039MGS-0039MGS 0039

Targets

GRM3 (mGluR3)

Beyond the preview

Go deeper on BCI-1038.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCI-1038.

Explore the full profile